a more restricted form of latency (type I) where most viral gene expression is silenced by 26 promoter DNA methylation. How EBV converts latency type is unclear, although it is known 27 that type I latency is associated with germinal center (GC) B cell phenotype, and type III latency 28
with an activated B-cell (ABC) phenotype. Here we have examined whether expression of TET2, 29 a cellular enzyme that initiates DNA demethylation by converting 5-methylcytosine (5mC) into 30 5-hydroxymethylcytosine (5hmC), regulates EBV latency type in B cells. We find that TET2 31 expression is inhibited in normal GC cells, and GC type lymphomas. In contrast, TET2 is 32 expressed in normal naïve B cells and ABC type lymphomas. We also demonstrate that GC type 33 cell lines have increased 5mC levels, and reduced 5hmC levels, in comparison to ABC type 34 lines. Finally, we show that TET2 promotes the ability of the EBV-transcription factor, EBNA2, 35 to convert EBV-infected cells from type I to type III latency. These findings demonstrate that 36 TET2 expression is repressed in GC cells independent of EBV infection, and suggest that TET2 37 promotes type III EBV latency in B cells with an ABC or naïve phenotype by enhancing EBNA2 38 activation of methylated EBV promoters. Following EBV infection of B cells, the virus initially establishes type III latency. The 69 first latent viral transcript expressed is derived from the EBV Wp promoter, and is biscistronic, 70 encoding both EBNA2 and EBNA-LP (2). EBNA2, a transcription factor, then activates 71 expression of the EBV Cp promoter, which drives expression of all EBNA genes during type III 72 latency (including EBNA2), and promoters for the EBV latent membrane proteins (LMPs) (1, 2) . 73
The divergent LMP1/LMP2B promoter drives expression of the LMP1 and LMP2B genes, and 74 the LMP2A promoter drives the expression of LMP2A. interacting with the cellular transcription factor, RBP-Jκ, which binds to sites in the C promoter 77 (7). EBNA2 also interacts with RBP-Jκ to activate LMP2Ap (8). In the case of the 78 LMP1/LMP2B promoter, EBNA2 interacts with RBP-Jκ as well as the cellular transcription 79 factor PU.1 to activate transcription (9). In addition, many EBNA2 binding sites in the cellular 80 genome have been shown to co-localize with binding sites for the essential B cell differentiation 81 factor, EBF1, as well as other cellular transcription factors (10). 82
During type I latency, the Cp promoter and EBNA2 expression is turned off, and EBNA1 83 transcription is instead regulated by the viral Q promoter (Qp). The EBV genome becomes 84 highly methylated during the establishment of type I latency, and stringent type I gene 85 expression is enforced in part by CpG methylation of the viral Cp, LMP1/2B, and LMP2A 86 promoters (11, 12). In contrast, the Cp, LMP1/LMP2B, and LMP2A promoters remain 87 unmethylated in cells with type III latency. Treatment of cells exhibiting type I latency with 88 demethylating agents is sufficient to convert cells to type III latency (13). Furthermore, the 89 ability of the Cp and LMP1/LMP2B promoters to be activated by EBNA2 in transient reporter 90 gene assays has been previously shown to be inhibited by promoter methylation (14, 15 expressed the TET2 transcript, while the lines that maintained a type I EBV latent infection did 258 not express TET2 (Fig. 1A) . In contrast, TET3 expression was similar in all cells lines (Fig. 1A ) 259 EBV latency type was determined by EBNA3C expression (Fig. 1A) , which is expressed in type 260 III but not type I latency. Immunoblot analysis of cell lines derived from the same BL tumor 261 (Kem) that had either type I latency (Kem I) versus type III latency (Kem III) confirmed that 262 TET2 protein is expressed in Kem III cells but not Kem I cells (Fig. 1B) . Similar results were 263 obtained in Mutu I vs. Mutu III cells (data not shown). As previously reported, type I lines had a 264 GC phenotype (BCL6+/IRF4-) whereas type III lines had an ABC phenotype (BCL6-265 /IRF4+) (Fig. 1B) . These results suggest that EBV proteins specifically expressed in type III (but 266 in loss of 5hmC and 5mC on the EBV genome), and isolated total DNA was immunoprecipitated 313 using antibodies that specifically detect 5hmC-or 5mC-modified DNA. As expected, the EBV 314 Cp promoter is highly methylated in Mutu I cells (where the promoter is silent) (Fig. 5) , and 315 much less methylated in Mutu III cells (where the promoter is active). In contrast, the Cp had 316 little or no 5hmC modification in Mutu I cells (in which TET2 is not expressed), but had 317 detectable 5hmC modification in Mutu III cells (which express TET2) (Fig. 5) . These data 318 suggest that TET2 expressed in EBV-infected cell lines can target methylated type III latency 319 promoters for 5hmC modification, which subsequently may promote demethylation and 320 activation of these promoters. 321 promoter. Importantly, however, co-expression of TET2 greatly increased the ability of EBNA2 337 to activate the methylated form of LMP1p (Fig. 6) . These results suggest that TET2 is required 338 for efficient activation of methylated LMP1 promoter by EBNA2. 339 have not yet undergone viral genome methylation. Given the ability of type I Burkitt lines to 386 switch to type III latency, and to lose cytosine methylation of the latency III promoters, we 387 hypothesized that the demethylating functions of cellular TET protein(s) might be involved in 388 this phenomenon. 389
TET2 expression enhances EBNA2-mediated type III latency gene expression from the
Here we have unexpectedly discovered that B cell lymphomas with a GC phenotype 390 (regardless of whether they are EBV infected or not) express little, if any, TET2 (Figs. 1 and 2) , 391 and that likewise normal tonsillar GC cells express much less TET2 than normal naïve B cells 392 (Fig. 3) . Furthermore, we find that lymphoma cells with a GC phenotype have globally 393 decreased 5hmC-modified DNA, and globally increased 5mC modified DNA, in comparison to 394 their ABC counterparts (Fig. 4) , and that this effect is EBV-independent. In support of our 395 findings here, examination of the TET 1, 2, and 3 transcript levels reported in a recently 396 published RNA seq data set from four human GC DLBCL cell lines and four human ABC 397 As previously reported by other groups (19), we found that type III latency in BL cells is 418 associated with an ABC phenotype, while type I latency is associated with a GC phenotype (Fig.  419   1) . Since the EBV EBNA2 latency protein is the key transcription factor required for activation 420 on December 28, 2016 by Univ of Wisconsin -Madison http://jvi.asm.org/ Downloaded from 22 of type III latency viral promoters, we examined how methylation of the LMP1 promoter (the 421 major viral oncoprotein) affects its ability to be activated by EBNA2. We find that cytosine 422 methylation of the LMP1 promoter greatly decreases the ability of EBNA2 to activate the 423 promoter in reporter gene assays, and that co-transfection with a constitutively active TET2 424 vector reverses this effect (Fig. 6) . Furthermore, TET2 greatly enhances the ability of EBNA2 to 425 activate expression of the methylated LMP1 promoter from the endogenous viral genome in BL 426 cells with type I latency (Fig. 7) . Thus, lack of TET2 expression in GC cells may promote type 
